Dogwood Therapeutics (NASDAQ:DWTX) Trading Up 0.7% – What’s Next?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) shares were up 0.7% during trading on Friday . The stock traded as high as $1.47 and last traded at $1.42. Approximately 40,106 shares traded hands during trading, a decline of 62% from the average session volume of 105,357 shares. The stock had previously closed at $1.41.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DWTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. Weiss Ratings cut shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Up 0.7%

The stock has a market capitalization of $47.75 million, a P/E ratio of -0.13 and a beta of 1.70. The stock has a 50 day simple moving average of $1.61 and a two-hundred day simple moving average of $2.38.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. Sell-side analysts predict that Dogwood Therapeutics, Inc will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.